[1-(1-Naphthalenyl)-2-oxo-2-[3-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]-2-naphthalenyl]ethyl]-phosphonic acid | 518062-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [1-(1-Naphthalenyl)-2-oxo-2-[3-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]-2-naphthalenyl]ethyl]-phosphonic acid
• 英文别名: [1-Naphthalen-1-yl-2-oxo-2-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carbonyl)naphthalen-2-yl]ethyl]phosphonic acid
• CAS: 518062-20-9
• 化学式: C₃₆H₃₂N₃O₆P
• 分子量: 633.64
• InChiKey: RTGRVDIUIXTQHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  46
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Novel phosphonic acid compounds as inhibitors of serine proteases
  申请人：——

  公开号：US20030195172A1

  公开（公告）日：2003-10-16

  The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.

  本发明涉及磷酸化合物，可用作丝氨酸蛋白酶抑制剂，以及这些化合物的组合物和治疗炎症和丝氨酸蛋白酶介导的疾病的方法。
• [EN] PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES<br/>[FR] COMPOSES D'ACIDE PHOSPHONIQUE UTILISES COMME INHIBITEURS DE SERINE PROTEASES
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2003035654A1

  公开（公告）日：2003-05-01

  The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.

  本发明涉及磷酸类化合物，其作为丝氨酸蛋白酶抑制剂有用，以及其组成物和用于治疗炎症和丝氨酸蛋白酶介导的疾病的方法。
• PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1438316B1

  公开（公告）日：2006-06-21
• PIPERAZINE CONTAINING PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
  申请人：Ortho-Mcneil Pharmaceutical Corp.

  公开号：EP1620446B1

  公开（公告）日：2012-10-24
• Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
  申请人：Talley John Jeffrey

  公开号：US20090054319A1

  公开（公告）日：2009-02-26

  The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.